World’s First New TB Vaccine Trial Hits Enrollment Target Early
A Phase 3 study of the M72/AS01E vaccine has successfully recruited its target of 20,000 participants in five countries, exceeding expectations. The trial, which began delivering shots last March, aims to test the two-dose vaccine’s safety and efficacy in preventing tuberculosis (TB) cases. The vaccine, developed by the Gates Medical Research Institute, is designed to … Read more